Locoregional chemoembolic delivery: Prediction with transcatheter intraarterial perfusion MRI

American Journal of Roentgenology

Volumn 198, Issue 5, 2012, Pages 1196-1202

  Gaba, Ron C ^a   Jin, Brian ^b   Wang, Dingxin ^b,c   Lewandowski, Robert J ^b   Ragin, Ann B ^b   Larson, Andrew C ^b,c   Salem, Riad ^b   Omary, Reed A ^b,c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Northwestern University   (United States)

Author keywords

Chemoembolization; Drug delivery; Hepatocellular carcinoma; MRI; Transarterial chemoembolization; Transcatheter intraarterial perfusion

Indexed keywords

CISPLATIN; DOXORUBICIN; GADOLINIUM PENTETATE MEGLUMINE; MITOMYCIN C;

AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER SIZE; CHEMOEMBOLIC DELIVERY SELECTIVITY FACTOR; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION COEFFICIENT; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER PERFUSION; MAJOR CLINICAL STUDY; MALE; PERFUSION WEIGHTED IMAGING; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOLOGICAL PARAMETERS; VOLUME OF DISTRIBUTION;

AGED; CARCINOMA, HEPATOCELLULAR; CATHETERIZATION; CHEMOEMBOLIZATION, THERAPEUTIC; CISPLATIN; CONTRAST MEDIA; DOXORUBICIN; ETHIODIZED OIL; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IOHEXOL; LINEAR MODELS; LIVER NEOPLASMS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MICROSPHERES; MITOMYCIN; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84860351088     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.11.7412     Document Type: Article

References (42)

1. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127(suppl 1):S5-S16 (Pubitemid 39423365)
2. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35:519-524 (Pubitemid 34183954)
3. Marcos-Alvarez A, Jenkins RL, Washburn WK, et al. Multimodality treatment of hepatocellular carcinoma in a hepatobiliary specialty center. Arch Surg 1996; 131:292-298 (Pubitemid 26078816)
4. Gaba RC. A survey of chemoembolization practice patterns and technical methodologies among interventional radiologists. (abstr) J Vasc Interv Radiol 2011; 22:S119-S120
5. Satake M, Uchida H, Arai Y, et al. Transcatheter arterial chemoembolization (TACE) with lipiodol to treat hepatocellular carcinoma: survey results from the TACE study group of Japan. Cardiovasc Intervent Radiol 2008; 31:756-761
6. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359:1734-1739 (Pubitemid 34607087)
7. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcino ma. Hepatology 2002; 35:1164-1171 (Pubitemid 34454013)
8. Arepally A. Targeted drug delivery under MRI guidance. J Magn Reson Imaging 2008; 27:292-298 (Pubitemid 351214037)
9. Virmani S, Ryu RK, Sato KT, et al. Effect of Carm angiographic CT on transcatheter arterial chemoembolization of liver tumors. J Vasc Interv Radiol 2007; 18:1305-1309 (Pubitemid 47446273)
10. Wallace MJ, Murthy R, Kamat PP, et al. Impact of C-arm CT on hepatic arterial interventions for hepatic malignancies. J Vasc Interv Radiol 2007; 18:1500-1507 (Pubitemid 350151867)
11. Kothary N, Abdelmaksoud MH, Tognolini A, et al. Imaging guidance with C-arm CT: prospective evaluation of its impact on patient radiation exposure during transhepatic arterial chemoembolization. J Vasc Interv Radiol 2011; 22:1535-1543
12. Artemov D, Solaiyappan M, Bhujwalla ZM. Magnetic resonance pharmacoangiography to detect and predict chemotherapy delivery to solid tumors. Cancer Res 2001; 61:3039-3044 (Pubitemid 32691952)
13. Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 2006; 24:3293-3298 (Pubitemid 46622069)
14. Padhani AR, Leach MO. Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Abdom Imaging 2005; 30:324-341 (Pubitemid 40898066)
15. Wang D, Bangash AK, Rhee TK, et al. Liver tumors: monitoring embolization in rabbits with VX2 tumors - transcatheter intraarterial first-pass perfusion MR imaging. Radiology 2007; 245: 130-139 (Pubitemid 47417796)
16. Gaba RC, Wang D, Lewandowski RJ, et al. Fourdimensional transcatheter intraarterial perfusion MR imaging for monitoring chemoembolization of hepatocellular carcinoma: preliminary results. J Vasc Interv Radiol 2008; 19:1589-1595
17. Larson AC, Wang D, Atassi B, et al. Transcatheter intraarterial perfusion: MR monitoring of chemoembolization for hepatocellular carcinoma - feasibility of initial clinical translation. Radiology 2008; 246:964-971
18. Virmani S, Wang D, Harris KR, et al. Comparison of transcatheter intraarterial perfusion MR imaging and fluorescent microsphere perfusion measurements during transcatheter arterial embolization of rabbit liver tumors. J Vasc Interv Radiol 2007; 18:1280-1286 (Pubitemid 47446275)
19. Wang D, Jin B, Lewandowski RJ, et al. Quantitative 4D transcatheter intraarterial perfusion MRI for monitoring chemoembolization of hepatocellular carcinoma. J Magn Reson Imaging 2010; 31:1106-1116
20. Lewandowski RJ, Tepper J, Wang D, et al. MR imaging perfusion mismatch: a technique to verify successful targeting of liver tumors during transcatheter arterial chemoembolization. J Vasc Interv Radiol 2008; 19:698-705
21. Blasberg RG, Kobayashi T, Patlak CS, et al. Regional blood flow, capillary permeability, and glucose utilization in two brain tumor models: preliminary observations and pharmacokinetic implications. Cancer Treat Rep 1981; 65(suppl 2):3-12 (Pubitemid 13246902)
22. Brown DB, Cardella JF, Sacks D, et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 2009; 20(7 suppl):S219-S226
23. Georgiades CS, Hong K, D'Angelo M, Geschwind JF. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005; 16:1653-1659 (Pubitemid 44431162)
24. Wang D, Zuehlsdorff S, Larson AC. Rapid 3D radiofrequency field mapping using catalyzed double-angle method. NMR Biomed 2009; 22:882-890
25. Omary RA, Henseler KP, Unal O, et al. Validation of injection parameters for catheter-directed intraarterial gadolinium-enhanced MR angiography. Acad Radiol 2002; 9:172-185 (Pubitemid 34184165)
26. Tandon P, Farahani K. NCI image-guided drug delivery summit. Cancer Res 2011; 71:314-317
27. Caturelli E, Siena DA, Fusilli S, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of damage to nontumorous liver tissue - long-term prospective study. Radiology 2000; 215:123-128 (Pubitemid 30190520)
28. Buijs M, Vossen JA, Frangakis C, et al. Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization- single-center experience. Radiology 2008; 249:346-354
29. Lewandowski RJ, Wang D, Gehl J, et al. A comparison of chemoembolization endpoints using angiographic versus transcatheter intraarterial perfusion/MR imaging monitoring. J Vasc Interv Radiol 2007; 18:1249-1257 (Pubitemid 47449750)
30. Geschwind JF, Salem R, Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004; 127(suppl 1): S194-S205 (Pubitemid 39423388)
31. Barraud L, Merle P, Soma E, et al. Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J Hepatol 2005; 42:736-743
32. Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind JF. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 2006; 12:2563-2567
33. Lewis AL, Gonzalez MV, Lloyd AW, et al. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 2006; 17:335-342 (Pubitemid 44341453)
34. Kopecek J, Kopeckova P, Minko T, Lu Z. HPMA copolymer - anticancer drug conjugates: design, activity, and mechanism of action. Eur J Pharm Biopharm 2000; 50:61-81 (Pubitemid 30326689)
35. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003; 2:347-360 (Pubitemid 37361705)
36. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 2006; 98:335-344 (Pubitemid 43338213)
37. Maeda H, Seymour LW, Miyamoto Y. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug Chem 1992; 3:351-362
38. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004; 127(suppl 1):S179-S188 (Pubitemid 39423386)
39. Sevick EM, Jain RK. Geometric resistance to blood flow in solid tumors perfused ex vivo: effects of tumor size and perfusion pressure. Cancer Res 1989; 49:3506-3512 (Pubitemid 19178166)
40. Monsky WL, Raptopoulos V, Keogan MT, et al. Reproducibility of linear tumor measurements using PACS: comparison of caliper method with edge-tracing method. Eur Radiol 2004; 14:519-525 (Pubitemid 38324929)
41. Jerosch-Herold M, Wilke N, Wang Y, et al. Direct comparison of an intravascular and an extracellular contrast agent for quantification of myocardial perfusion. Cardiac MRI Group. Int J Card Imaging 1999; 15:453-464 (Pubitemid 30189171)
42. Canty JM Jr, Judd RM, Brody AS, Klocke FJ. First-pass entry of nonionic contrast agent into the myocardial extravascular space: effects on radiographic estimates of transit time and blood volume. Circulation 1991; 84:2071-2078